- Home
- NKX vs ORIC Comparison
NKX vs ORIC Comparison
Compare NKX & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NKX | ORIC |
|---|---|---|
| Founded | 2002 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 645.5M | 973.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NKX | ORIC |
|---|---|---|
| Price | $12.73 | $9.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 109.3K | ★ 1.3M |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 4.37% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.78 | $3.90 |
| 52 Week High | $12.00 | $14.93 |
Technical Indicators
Market Signals| Indicator | NKX | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 45.50 | 28.43 |
| Support Level | $12.70 | $10.45 |
| Resistance Level | $12.80 | $12.50 |
| Average True Range (ATR) | 0.06 | 0.72 |
| MACD | -0.01 | -0.18 |
| Stochastic Oscillator | 20.83 | 3.87 |
Price Performance
Historical ComparisonAbout NKX Nuveen California AMT-Free Quality Municipal Income Fund
Nuveen California AMT-Free Quality Municipal Income Fund is a closed-end fixed income mutual fund. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. It invests across sectors such as healthcare, utilities, transportation, and housing.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.